Whipplewood Advisors LLC Buys New Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 345 shares of the company’s stock, valued at approximately $28,000.

A number of other institutional investors have also modified their holdings of the stock. Blue Trust Inc. boosted its position in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. acquired a new stake in Vaxcyte during the third quarter valued at $92,000. AlphaCentric Advisors LLC acquired a new stake in Vaxcyte during the fourth quarter valued at $161,000. Finally, Nisa Investment Advisors LLC increased its holdings in Vaxcyte by 5.2% in the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock valued at $252,000 after buying an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In other news, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $92.25, for a total value of $218,263.50. Following the completion of the sale, the chief executive officer now directly owns 136,215 shares in the company, valued at $12,565,833.75. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total value of $670,800.00. Following the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,180,820.35. The trade was a 6.81 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 76,616 shares of company stock valued at $6,766,481. Corporate insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday. The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Finally, Guggenheim reiterated a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $147.50.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $73.02 on Friday. The business has a 50 day simple moving average of $84.59 and a two-hundred day simple moving average of $94.83. The stock has a market capitalization of $9.40 billion, a P/E ratio of -15.87 and a beta of 0.98. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.